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Abstract 
After injection of Sendai virus, a parainfluenza virus type 1, mice generate 
cytotoxic lymphocytes which lyse specifically Sendai-virus-infected target cells 
in v i t ro . Their action is not inhibited by specific antibody i n v i t ro . Kil ler cell 
act ivi ty appears 4 days after infection, reaches a max imum on the 7th day and 
disappears on the 14th to 16th day. Decrease of cytotoxic cell ac t iv i ty is corre-
lated wi th an increase of haemagglutinating antibodies. The cytotoxic effector 
cell could be characterized as a thymus-derived cell, there is no specific activi ty 
in antibody-dependent cell-mediated cytolysis (ADCC). 
The degree of cytotoxic effector cell ac t iv i ty is only slightly influenced by the 
dose of injected infective virus. 
*) This work was supported by the Deutsche Forschungsgemeinschaft. 
List of Abbreviations 
ADCC = antibody-dependent cell-mediated cyto toxic i ty 
CFA = complete Freund\s adjuvant 
CL = cytotoxic lymphocytes 
CMC = cell-mediated Cytotoxici ty 
CRBC = chicken red blood cell 
E I D 5 0 ==50% egg infective dose 
E-monolayer = monolayer of CRBC 
EA-monolayer = monolayer of CRBC coated w i t h antibodies to CRBC 
i.p. = intraperitoneal 
LCM = lymphocytic choriomeningitis 
= 50% lethal dose L D 5 0 
M E M = minimal essential medium 
N-modifiecl = N-(3-ni t ro-4-hydroxy-5- iodophenylacetyl) -ß-alanylglycyl-
glycyl-modified 
NMS = normal mouse serum 
PBS = phosphate buffered saline 
rpm = revolution per minute 
SD-antigen = Serologically defined antigen 
SRBC = Sheep red blood cell 
T C I D 5 0 = 50% tissue culture infective dose 
TNP = Trinitrophenyl 
T cell = Thymus-derived cell 
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Using different syngeneic Sendai-virus-infected cells as targets for cell-medi-
ated cytotoxic i ty , a tumor line was not lysed by cytotoxic lymphocytes in spite 
of v i ra l surface antigens. 
Preliminary experiments were performed to demonstrate the H-2 gene re-
str ict ion of the cytotoxic interaction. Using macrophages and tumor cells as 
targets only syngeneic infected target cells were lysed. 
Introduction 
Infect ion w i t h some viruses results i n the generation of cytotoxic 
effector cells. I n the mouse viruses of 2 groups, 1 arenavirus (LCM-
virus) and 2 poxviruses (Vaccinia and Ectromelia virus) have been 
well studied ( 1 , 2, 3 ) . I n these systems the C3 'totoxic effector cells have 
been shown to be thymus-derived cells, which selectively lyse target 
cells expressing the same H - 2 serologically defined antigens as the 
effector cells. 
Similar immune reactions are induced in vivo by several syngeneic 
tumor cells ( 4 ) or by H - Y differences ( 5 ) and in vitro by T N P - or N -
modified syngeneic st imulator cells ( 6 , 7 ) . 
The 2 v i r a l systems show similarities such as H - 2 restriction and 
virus specificity bu t also some differences. I n the LCM-virus-system 
P F I Z E N M A I E R et al. ( 8 ) observed 2 - 5 days after the infection early 
ki l ler cells, which lyse uninfected syngeneic cells. Such self-reactive 
cells were not found i n the Vaccinia virus infection. 
The cytolysis of Vaccinia-virus-infected cells was specifically in -
hibi ted by anti-Vaccinia virus serum ( 9 ) . Inh ib i t ion of cytotoxici ty 
was seen w i t h ant i -v i ra l sera i n the Sindbis virus infection ( 1 0 ) and 
w i t h antiserum to T N P i n the effector phase against TNP-modified 
target cells ( 1 1 ) . These effects were not found in the LCM-system 
( P F I Z E N M A I E R , pers. communication). 
To study the significance of these differences, the investigations 
should be extended to other v i r a l infections. Data presented here show 
generation, turnover and specificity of cytotoxic effector cells after 
infection of mice w i t h Sendai virus, a para-influenza virus type 1, an 
R N A virus which maturates by a budding process in the same way as 
L C M virus. 
Materials and Methods 
1. Viruses 
Sendai virus - strain D-52 (Behring werke A G , Marburg/Lahn) - was propa-
gated in the allantoic fluid of 10 days-old fertile eggs. The 27th passage was 
used throughout. The virus was di luted to a titer of 107 E I D 5 0 per m l . 
Vaccinia virus - strain W R was propagated on V E R O (monkey kidney cells) 
or on O M K (owl monkey kidney cells) cells and diluted to a titer of 105-5 T C I D 5 0 
per m l . 
L C M virus - strain WE-3 , k ind ly provided by Dr. L E H M A N N - G R U B E , Ham-
burg, was used i n a concentration of 300 L D 5 0 per ml . 
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2. Mice 
Inbred mice of strains C 3 H (H-2*), DBA/2 (H-2<i), A K R (H-2*) and C57B1/6 
(H-2 1 3), purchased from B . L . Bomholdgard, Ry, Denmark, were used at the 
age of 8-12 weeks. 
3. Antisera 
Antiserum to Sendai virus was prepared as described elsewhere (12). A n t i - 0 -
serum was raised in A K R mice according to the method of R E I F and A L L E N (13). 
The serum was absorbed wi th C 3 H bone marrow cells before use. 
4. Separation of IgG-bearing cells and Macrophages 
Immunoglobulin-bearing cells were eliminated by adherence to nylon wool 
columns (14). The decrease of IgG-positive cells was monitored by immuno-
fluorescence. Macrophages were eliminated by adsorption of spleen cell suspen-
sions on plastic surfaces. 
5. Testing and elimination of ADCC effector cells 
Absorption of Fc-bearing lymphocytes was performed on antibody-coated 
chicken red blood cell (CRBC) monolayers according to the method of K E D A R 
et al. (15). Efficiency of the absorption was tested in ADCC. The same volume 
of rabbit antiserum* to CRBC (diluted 1:1000, ti ter in ADCC 1:60,000), was 
added to 5 X 104 5 1Cr-labelled CRBC in a volume of 0.05 m l (sodium chromat, 
Amersham, Buchler, Braunschweig, No CMS I P , spec, act ivi ty 100-200 mCi/mg 
Cr). Absorbed or not absorbed lymphocytes (5 X 106) were incubated wi th the 
antibody-coated erythrocytes over a period of 4 hours. For calculation super-
natants and pellets were harvested separately and 5 1Cr release was determined 
according to the formula: 
, w , radioactivity in supernatant , 
% 5 1Cr release = - — - x 100 
radioactivity in supernatant + pellet 
Specific lysis was calculated by subtracting 5 1Cr release in the presence of 
CRBC + antibody without lymphocytes from 5 1Cr release in the presence of 
CRBC - j - antibody + lymphocytes. 
6. Indirect immunofluorescence 
Indirect immunofluorescence of viral surface antigens on viable infected cells 
was performed as described previously (16). 
7. Target cells 
L-929 cells (H-2 k ) were grown as monolayers in Eagles minimal essential 
medium supplemented wi th 10% calf serum and 100 //g/ml penicillin and 
streptomycin. Mastocytoma P-815 (H-2^), Meth A (H-2 d ) and EL-4 (H-2 b ) 
tumour cells, k indly provided by Dr. SCHIRRMACHER, Heidelberg, were serially 
passaged at 8-10 days intervals in the peritoneal cavity of syngeneic mice. 
Macrophages were harvested 3 days after i.p. injection of 2 m l thioglycollate 
and separated from other cells by affinity to glass or plastic surfaces and trypsin 
resistance. 
S. Infection of target cells 
A volume of 0.5 m l Sendai virus diluted i n 20 m l medium was added to about 
1-2 x 107 L-929 monolayer cells. 1 hour later the medium containing virus was 
discarded and fresh medium was added. Tumour cells (5 X 106 i n 5 ml) were 
infected for 1 hour w i t h 0.2 ml Sendai virus, centrifuged and resuspencled in 
fresh medium. Macrophages were cultivated for 4 hours in petri dishes. The 
non-adherent cells were removed and 0.2 m l Sendai virus was added. After 
1 hour incubation the virus-containing fluid was replaced by fresh medium. 
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9. Cytotoxic assay 
The assay was performed wi th some modifications according to the method 
of B R U N N E R et al. ( 1 7 ) and W A G N E R ( 1 8 ) . The number of 5 x 10* 1 4 hour in-
fected or uninfected 5 lCr-labelled target cells were incubated w i t h 5 X 10 6 l ym-
phocytes of normal mice or mice immunized 7 days previously w i t h Sendai virus 
in a volume of 1.0 ml in plastic tubes. Spontanous lysis was determined by 
adding medium instead of lymphocytes, the maximal lysis was determined by 
adding 1 m HCl to the target cells. After 8 hours of incubation supernatants 
and cells were harvested seperately. 
The % 5 1Cr release was calculated using the formula: 
„, _ counts in the supernatant 
% 0 l Cr release = X 100 
counts in the supernatant + in the pellet 
Specific lysis was calculated by subtraction of % 5 1Cr release in the presence 
of normal lymphocytes from % 5 1Cr release in the presence of immune lympho-
cytes. 
Assays were done at least in triplicate, SD values of all data presented here 
were less than 5%. Significance was calculated using the student t-test. 
Results 
1. Kinetics of development of cytotoxic lymphocytes in vivo 
Eight groups of 4 C 3 H mice were injected i.p. at 2 day intervals 
w i t h 1 m l Sendai virus containing 1 0 7 E I D 5 0 per ml . 2 days after the 
last injection the spleen lymphocytes were harvested and tested for 
2 4 6 5 70 12 14 To 
DAYS AFTER INFECTION WITH SENDAI VIRUS 
Fig. 1. Specific cytotoxicity against Sendai-virus-infected L-929 cells of spleen 
lymphocytes harvested from 8 groups of animals infected wi th Sendai virus 
( 1 0 7 E I D 5 0 ) . % Specific lysis was calculated by subtraction of % Cr release 
caused by normal spleen cells from % Cr release caused by immune spleen cells. 
Each point represents the mean of 4 wells. 
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DAYS AFTER INFECTION 
Fig. 2. Ac t iv i t y of anti-Sendai-virus serum from C 3 H mice infected 4, 8, 12, 16 
and 30 days previously, was tested in a haemagglutination inhibit ion assay. 
cytotoxici ty on Sendai-virus-infected and normal L - 9 2 9 target cells at 
an effector cell to target cell ratio of 1 0 0 : 1 . Spleen lymphoc}^tes of 
normal animals were used as controls. Significant cytolysis was ob-
served on day 4 after infection, reaching a maximum on day 7 - 8 
(Fig. 1 ) , 2 weeks after infection only weak cytotoxici ty was detectable. 
2. Kinetics of development of antibody in vivo 
The antibody- t i ter of C 3 H mice injected 4 , 8, 12, 1 6 and 3 0 days 
previously w i t h Sendai virus was tested in the haemagglutination in -
hibit ion assay. As shown in Figure 2 antibody activities against Sendai 
virus were found on day 1 2 - 1 6 . 
Tab. 1. Effect of anti-Sendai serum on cell-mediated cytotoxici ty. Specific lysis 
of Sendai-virus-infected L-929 cells by immune C 3 H lymphocytes was tested 
in the presence of normal mouse serum and anti-Sendai -virus serum raised in 
C 3 H mice. 
Target cell Effector Serum /o 
cell spec. Lysis 
L-929, Sendai-virus-infected C 3 H _ 30.2 
normal 20.4 
anti-Sendai - virus 36.2 
E L 4 , Sendai-virus-infected C57B1/6 - 22.7 
normal 18.4 
anti-Sendai - virus 29.9 
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3. Effect of anti-Sendai-virus serum on cell-mediated cytolysis 
The incubation of target cells and effector cells i n the presence of 
anti-Sendai-virus serum (titer 1:1024, final di lut ion 1:4) caused no 
inhibi t ion of cell-mediated cytolysis in an 18 hours assay. I n some 
experiments even a slight increase of specific lysis could be observed 
(Tab. 1). 
4. Dose of in vivo injected virus and in vitro cytotoxic activity 
C 3 H mice were infected by i.p. injection w i t h Sendai virus diluted 
serially 10-fold w i t h medium. Seven days later the spleen cells were 
harvested and the cytotoxic assay was performed. L i t t l e relationship 
w i t h the amount of injected, infective virus could be observed. Lympho-
cytes of animals which received 101 E I D 5 0 virus showed the same 
ac t iv i ty as lymphocytes of animals which obtained 107 E I D 5 0 virus 
(Fig. 3). This indicates that the degree of ant iviral CMC is independent 
of the primary- dose. Only lymphocytes of animals which were infected 
w i t h more than 108 E I D 5 0 virus showed higher cytotoxici ty. About 
50% of these mice died 4-5 days after infection. 
5. Efficiency of target cell lysis in vitro 
The act ivi ty of day 7 immune C 3 H lymphocytes on Sendai-virus-
infected L-929 cells was tested using different ratios of target cells to 
lymphocytes. As control, spleen lymphocytes of normal mice were 
50-, 
10 
lO 5 10 7 10 5 103 1Ö1 E I D ^ 
INJECTED DOSIS OF SENDAI VIRUS 
Fig. 3. Specific cytotoxicity against Sendai-virus-infected L-929 cells of spleen 
lymphocytes from animals infected 7 days previously wi th Sendai virus diluted 
serially 10-fold w i th medium was tested. 
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60-
5 10 2 0 5 0 100 200 
PERCENTAGE OF IMMUNE S P L E E N C E L L S TO 
TARGET CELLS 
Fig. 4. Effector to target cell ratios and percentage of virus-specific CMC (target 
cells: Sendai virus infected L-929 cells; effector cells: C 3 H spleen lymphocytes). 
% Specific tysis was calculated by subtraction of % Cr release in the presence 
of normal spleen cells from % Cr release in the presence of immune spleen cells, 
using the same ratios. 
added in the same ratios to the target cells. As seen in Figure 4 , 
maximal cytotoxici ty was obtained at ratios between 1 : 5 0 and 1 : 1 0 0 
target cell to effector cells. 
6. Virus specificity of cell-mediated cytolysis 
C 3 H mice were infected w i t h 10 5 - 5 T C I D 5 0 Vaccinia virus, 10 7 E1D 5 0 
Sendai virus or 300 L D 5 0 L C M virus. Spleen cell ac t iv i ty on Vaccinia-, 
Tab. 2. Specific lysis of Vaccinia-, LCM- or Sendai-virus-infected C 3 H macro-
phages by vaccinia, LCM or Sendai immune spleen lymphocytes was tested. 
Mean of 4 groups; differences are statistically significant (P < 0.001). 
Target cells % Specific Cytolysis 
Vaccinia virus Sendai virus 
immune C 3 H immune C 3 H 
lymphocytes lymphocytes 
L C M virus 
immune C 3 H 
lymphocytes 
Normal macrophages - 0 . 2 0.7 - 3 . 3 
Macrophages infected 
w i t h vaccinia virus 36.9 7.8 5.3 
Macrophages infected 
w i t h Sendai virus 1.1 42.2 1.7 
Macrophages infected 
w i t h LCM virus - 0 . 4 - 1 . 5 27.4 
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Sendai-, or LCM-virus-infected macrophages was tested on day 7. As 
seen in Table 2 only target cells infected with the same virus as used 
for sensitization were lysed by immune lymphocytes, no cross-reacti-
vity could be observed. 
7. Characterization of the cytotoxic effector cell 
Anti-0-serum: The number of 5 x 106 spleen lymphocytes from C3H 
mice sensitized 7 days previously to Sendai virus were incubated with 
0.5 ml A K R anti-0-serum for 30 minutes at 37° C, washed 2 times 
and then incubated for another period of 30 minutes in 0.5 ml guinea 
pig complement. The latter had been preabsorbed on L-929 cells. 
Control cells were incubated with complement or with anti-0-serum 
alone. The results (Tab. 3) show, that the effector cell is sensitive for 
anti-0-serum. 
Nylon wool column passage: To eliminate IgG-bearing cells the 
effector cells were passed through a nylon wool column (14). This 
procedure reduced the number of Ig-positive cells to 1-2% in the 
effluent fraction. Removal of B cells did not reduce virus-specific 
effector cell activity (Tab. 3). 
Adsorption on plastic dishes: Macrophages were removed by in-
cubation of effector cell suspensions (10 x 106) in 6 cm plastic dishes 
for 2 hours at 37 °C. Control absorptions were run at 4°C. The results 
indicate that macrophages are not significantly involved in specific 
killing of infected target cells (Tab. 3). 
Depletion of ADCC effector cells: Some inhibition assays with anti-
Sendai-virus serum gave a rise in specific cytolysis. We tested there-
fore the activity of the effector cells after absorption of Fc-positive 
cells on EA-monolayers or on control E-monoIayers. The efficiency of 
the separation was controlled by ADCC with CRBC target cells coated 
with rabbit anti-serum to CRBC (Tab. 4). The results suggest that Fc-
Tab. 3. Characterization of the Sendai-virus-specific cytotoxic effector cell. 
Mean % 5 , Cr release from groups of 3 tubes. Lymphocytes were harvested from 
C 3 H mice 7 days after i.p. sensitization wi th 1()7 E I D 5 0 Sendai virus. Significant 
reduction (P < 0.001) of target cell lysis after pretreatment of lymphocytes 
with anti-0-serum and complement. 
Pretreatment of immune lymphocytes % Specific lysis at an 
attacker: target cell ratio of 
100:1 10:1 
None 34.2 2.8 
Ant i-0-serum 23.8 0.7 
Complement 21.1 1.2 
Ant i-0-serum - j - complement 1.1 1.1 
Nylon wool column 34.1 4.9 
Absorption on plastic dishes 37.6 3.4 
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Tab. 4. Depletion of ADCC effector cells. Spleen cells originate from C 3 H mice 
inoculated (i.p.) 7 days previously wi th 107 E I D 5 0 Sendai virus. ADCC was per-
formed in a 4 hour assay, reduction of cytolysis on EA-monolayers is significant 
(P < 0.001). CMC was performed in an 8 hours assay. 
Cells Treatment Target cells 
CRBC L-929, 
ADCC CMC 
C 3 H spleen cells sensitized Control 62.9 34.2 
to Sendai virus E -monolayer adsorption 51.7 29.7 
EA-monolayer adsorption 20.4 32.7 
C 3 H spleen cells Control 62,4 0 
E-monolayer adsorption 58.4 0 
E A - mo nolay er adso r p t i on 20.9 0 
positive cells are not the effectors in this reaction. Table 5 shows the 
activity of sensitized effector cells before and after immunoabsorption 
in the presence of anti-Sendai-virus serum. There is no decrease of 
cytotoxicity after removal of Fc-positive cells. 
8. Lysis of different target cells by cytotoxic lymphocytes 
Spleen lymphocytes from sensitized C3H, DBA/2 and C57B1/6 
mice were tested for cytotoxic activity on syngeneic target cells. As 
target cells infected macrophages, fibroblasts and tumour cells were 
used. As seen in Table 6 infected macrophages were significantly lysed 
Tab. 5. Depletion of ADCC effector cells and cytolysis of target cells in the 
presence of antibodies. Spleen cells were obtained from C 3 H mice, infected 
7 days previously wi th 107 E I D 5 0 Sendai virus. Antiserum to Sendai virus was 
raised in mice, H H T titer was 1:1024, final di lut ion of serum in the test: 1:10. 
No significant differences of cytotoxic act ivi ty after addition of normal or anti-
viral serum to absorbed and non -absorbed spleen cells. 
Treatment of effector cells Serum added in vi t ro Specific cytolysis 
of Sendai-virus-
infected L-eel Is 
None _ 34.2 
NMS 39.0 
anti - Sendai - vir u s 
antibodies 37.5 
Absorption on EA-monolayers .._ 32.7 
NMS 38.7 
anti-Sendai-virus 
antibodies 39.8 
Absorption on E-monolayers _ 29.2 
NMS 38.4 
anti-Sendai-virus 
antibodies 33.9 
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Tab. 6. Data represent the mean of 4 groups. Standard error of the mean did 
not exceed 3%. 
Target cells Lymphocytes % Specific lysis at 
attacker: target cell ratio 
100:1 10:1 
H - 2 k Macrophages 3.9 - 1 . 1 
H - 2 k Macrophages, infected C3H 18.8 3.9 
L-929 - 1 . 0 3.1 
L-929, infected 37.9 1.8 
H - 2 d Macrophages D B A / 2 0.6 1.2 
H - 2 d Macrophages, infected 28.3 2.4 
P-815 1.5 0.9 
P-815, infected 20.5 1.4 
Meth A - 0 . 1 2.6 
Meth A, infected -1 .8 1.1 
C 57 Bl/6 Macrophages C 57 Bl/6 6.8 2.7 
C 57 Bl/6 Macrophages, infected 12.6 7.2 
EL-4 7.2 6.9 
EL-4 , infected 36.7 18.0 
b}' syngeneic sensitized lymphocytes. Using permanent cell lines in the 
H - 2 K system L - 9 2 9 cells were also killed. I n the H - 2 D system Masto-
cytoma P-815 cells were lysed in significant amounts by D B A / 2 
effector cells but syngeneic Meth A tumour cells were not affected. 
Immune C57Bl /6 lymphocytes kil led macrophages and EL-4 tumour 
cells as well . 
To control the percentage of infected cells, immunofluorescence 
studies w i t h anti-Sendai-virus serum were performed on viable cells. 
The results clearly indicate, that all cells that were lysed by syngeneic 
effector cells as well as the tumour cell line resistant to virus-specific 
lysis, expressed Sendai-virus-specific surface antigens. 
Tab. 7. I n vitro cytotoxici ty of Sendai-virus-sensitized C 3 H , DBA/2 and 
C 57 Bl/6 spleen cells to syngeneic and allogenic normal and Sendai-virus-
infected target cells at an attacker:target cell ratio of 100:1 and 10:1. 
Target cells % Specific lysis (8 hours assay) 
of the effector cells 
C 3 H DBA/2 C57 Bl/6 
100:1 10:1 100:1 10:1 100: 1 10:1 
C 3H-macrophages 3.1 0.9 - 3 . 3 - 2.2 - 2 . 1 4.8 
C 3H-macrophages, infected 14.8 3.1 - 6 . 8 - 2.1 0.1 2.9 
P-815 0 0.1 1.4 1.8 3.8 1.1 
P-815, infected - 0 . 1 0.1 14.3 0.7 3.6 4.9 
C 57 Bl/6-macrophages 0.6 0.8 - 1 . 0 5.4 5.4 2.2 
C57 Bl/6-macrophages, infected 2.5 1.4 - 8 . 4 3.3 10.6 5.8 
EL-4 0.8 2.2 n. t, 5.8 5.6 
EL-4, infected - 0 . 4 3.5 n. t . 30.4 14.3 
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9. H-2 gene restriction of effector cell activity 
Virus-specific sensitized cells from C 3 H (H-2 k ) , D B A / 2 d ) and 
C57B1/6 (H-2 b ) mice were incubated w i t h various target cells. Normal 
and infected tumour cell lines were used in this assay as well as normal 
and infected macrophages. The effector cells kil led only syngeneic 
infected target cells (Tab. 7). 
Discussion 
The data of the present investigation demonstrate, that mice i n -
fected w i t h Senclai virus, generate cytotoxic effector cells which are 
able to k i l l Sendai-virus-infected syngeneic target cells. 
The kinetics of the generation of cytotoxic lymphocytes in vivo 
were similar to the other experimental v i ra l systems (1, 3). Also 
in vitro conditions of target cell lysis using different effector to target 
cell ratios were comparable to other virus-specific cellular immune 
responses, maximal lysis was obtained w i t h a ratio between 50-100 
attacker cells to 1 target cell. 
The effector cells killed only infected but not non-infected syngeneic 
control target cells. P F I Z E N M A I E R et al. ( 8 ) found early self-reactive 
lymphocytes in vitro after experimental L C M virus infection in mice. 
Sendai and L C M viruses are both RNA-containing viruses which 
maturate by a budding process on the cell surface. Since we could not 
find self-reactive cells in the early stages of Sendai virus infection the 
generation of these cytotoxic cells does not generally characterize the 
cellular immune response to RNA-containing budding viruses. 
Haemagglutinating antibodies were demonstrable 8 days after the 
infection and reached a plateau after 12-16 da}^s. Thus, these anti-
bodies appeared at the same time as cytotoxic effector cell act ivi ty 
decreased. Possibly there is a correlation between disappearance of 
killer cells and rise of antibodies (19). 
Inhib i t ion of CMC by anti-Sendai-virus serum could not be ob-
served. I t is possible that an antibody which shows haemagglutination 
of Sendai virus does not react w i t h the target of CL. The slight in-
crease of cytotoxic effects in the presence of antibody cannot be 
at tr ibuted to an additional ac t iv i ty of non-tlvymus-derived, Fc-
receptor-bearing lymphocytes. Using different criteria for the char-
acterization of cytotoxic effector cells in vitro evidence was provided 
that the cytotoxic lymphocytes were thymus-derived cells. Adsorp-
tion of spleen cells from sensitized mice on EA-monolayers (15) did 
not decrease the specific act ivi ty of virus-activated T cells. The data 
show conclusively that the spleen cells contain ADCC effector cells 
against antibody-coated CRBC which can be specifically absorbed, 
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but there was no ADCC of Sendai-virus-infected cells in the presence 
of specific antibody. 
When we used various target cells, we could observe that in the H - 2 K , 
H - 2 D a n d H - 2 B systems syngeneic infected macrophages were generally 
ki l led. Infected L - 9 2 9 cells, mastocytoma P-815 or E L - 4 tumour cells 
were also lysed by syngeneic effector cells, sometimes even better than 
macrophages. However, Meth A cells were not kil led by cytotoxic 
lymphocytes in spite of v i ra l surface antigens. As i t was shown by 
L E S L E Y et al. ( 2 0 ) , different tumour cells are characterized by a rather 
low density of H - 2 antigens. I t is possible that infected tumour cells, 
which are not kil led by sensitized lymphocytes are marked b}^ a low 
content of H - 2 specificities or by a resistance to cell-mediated cyto-
lysis in vitro. Using Meth A cells as stimulator cells for in vitro induc-
t ion of allogenic C 3 H killer cells we could not obtain cytotoxic effector 
cells reactive against H - 2 D target cells. Testing C 3 H effector cells, 
sensitized in vitro against H - 2 D . we found lysis of D B A / 2 macrophages 
or mastocytoma P-815 tumour cells while Meth A cells were not ki l led 
(unpublished results). 
The results presented in Table 7 demonstrate that cytotoxic cells 
generated against Sendai-virus-infected target cells require H - 2 com-
pat ib i l i ty between effector and target cells. B y using congenic mouse 
strains virus-specific recognition of modified products of the I region 
and the M locus can be excluded. I n general, the specificity of the 
cytotoxic lymphocyte generated during Sendai-virus infection in mice 
seems to follow the same genetic restrictions described in the reaction 
towards viral- (2 , 3, 2 1 ) chemical- (6 , 7, 12) H - Y - (5) or minor histo-
compatibility antigen- ( 2 2 ) modified target cells. 
Acknowledgement 
We thank Ms. K . B . H E N D E R S O N and Ms. B . H U N D T for technical assistence, 
Mrs. I . D R E Y E R for preparation of the manuscript. 
References 
1. G A R D N E R , J . , R. V . B L A N D E N , and N . A . B O W E R N . 1974 . Cell-mediated cyto-
toxici ty against ectromelia virus infected target cells. I I . Identification of 
effector cells and analysis of mechanisms. Europ. J . Immunol . 4: 68 . 
2. K O S Z I N O W S K I , U . , and H . E R T L . 1975 . Lysis mediated by T-cells is restricted 
by H - 2 antigens of target cells infected wi th vaccinia virus. Nature 255: 2 5 4 . 
3. Z I N K E R N A G E L , R. M . , and P. C. D O H E R T Y . 1974 . Restriction of in vi tro T-cell 
mediated cytotoxicity in lymphocytic choriomeningitis wi th in a syngeneic 
or semiallogenic system. Nature 245: 7 0 1 . 
4. B H A T N A G A R , R. M . , I . B . Z A B R I S K I E , and A . R. R A U S E N . 1975 . Cellular 
immune response to methyl-cholantren induced fibrosarcoma in Balb/c mice. 
J. exp. Med. 142: 8 3 9 . 
5. GORDON, R. D . , E. SIMPSON, and L . E. SAMELSON. 1975 . I n vi t ro cell-
mediated immune responses to the male specific ( H - Y ) antigen in the mice. 
-T. exp. Med. 142: 1108 . 
140 • H . E R T L and U . K O S Z I N O W S K I 
6. SHEARER, G. M . 1974 . Cell-mediated cytotoxici ty to modified sj'ngoneic 
lymphocytes. Europ. J. Immunol . 4: 527 . 
7. R E H N , T . G., G. M . SHEARER, H . S. K O R E N , and J . K . I N M A N . 1976 . Cell-
mediated lympholysis of N-(3-nitro-4-hydroxy-o-iodophenylacety 1)-ß -alanyl-
glycylglycyl-modified autologous lymphocytes. Effector cell specificity to 
modified cell surface components controlled by the H - 2 K and H - 2 D 
serological regions of the murine major histocompatibility complex. J . exp. 
Med. 143: 127 . 
8. P F I Z E N M A I E R , K . , H . T R O S T M A N N , M . R Ö L L I N G H O F F , and H . W A G N E R . 1975 . 
Temporary presence of self-reactive cytotoxic T-lymphocytes during murine 
lymphocytic choriomeningitis. Nature 258: 2 3 8 . 
9. K O S Z I N O W S K I , U . , and R . THOMSSEN. 1974 . Target cell dependent T-cell 
mediated lysis of vaccinia virus-infected cells. Europ. J . Immunol . 5: 245 . 
10. M C F A R L A N D , H . F . 1974 . I n v i t ro studies of cell-mediated immuni ty in an 
acute viral infection. J . Immunol . 113: 7 1 2 . 
1 1 . S C H M I T T - V E R H U L S T , A . M . , D . H . SACHS, and G. M . SHEARER. 1976 . Cell-
mediated ly mpholysis of trinitrophenyl-modified autologous lymphocytes. 
Confirmation of genetic control of response to trinitrophenyl-modified H - 2 
antigens bv the use of an t i -H-2 and anti-Ia-antibodics. J . exp. Med. 143: 
2 1 1 . 
12. K I E L I N G , F . , G. B A N D L O W , and R . THOMSSEN. 1972 . Cytotoxic react ions 
w i t h Sendai virus infected cells. Arch . ges. Virusforsch. 36: 123 . 
13. R E I F , A. E . , and J. M . V. A L L E N . 1964 . The A K R thymic antigen and its 
distribution in leucemias and nervous tissues. J . exp. Med. 120: 4 1 3 . 
14. J U L I U S , M . , G . SIMPSON, and L . A. H E R Z E N B E R G . 1973 . A rapid method for 
the isolation of functional thymus derived lymphocytes. Europ. J . Immunol . 
3: 6 4 5 . 
15. K E D A R , R., M . O R T I Z D E L A N D A Z U R I , and B . B O N A V I D A . 1 9 7 4 . Cellular 
immunoadsorbents: a simplified technique for separation of lymphoid cell 
populations. J . Immunol . 112: 1 2 3 1 . 
16. K O S Z I N O W S K I , U . , and H . E R T L . 1975 . Altered serological and cellular 
reactivity to H - 2 antigen after target cell infection wi th vaccinia virus. 
Nature 257: 5 9 6 . 
17. B R U N N E R , K . T., J . M A U E L , J . C. C E R O T T I N I , and B . CHAPUIS . 1970 . Quanti-
tative assay of the lyt ic action of immune lymphoid cells of 51-Cr labeled 
allogenic target cells in vi t ro inhibi t ion by isoantibodies and by drugs. 
Immunol . 18: 5 0 1 . 
18. W A G N E R , H . 1973 . Synergy during in vi tro cytotoxic allograft responses. 
J . exp. Med. 138: 1379 . 
19. L A G R A N G E , P. H . , G . B . MACKANESS, and T. E. M I L L E R . 1974 . Potentiation 
of T-cell-mediated immunity by selective suppression of antibody forma-
tion wi th cyclophosphamide. J . exp. Med. 132: 1529 . 
2 0 . L E S L E Y , J. , R. H Y M A N , and G . D E N N E R T . 1974 . Effect of antigen density on 
complement-mediated lysis, T-cell-mediated ki l l ing and antigenic modula-
t ion. J . Nat. Cane. Inst. 52: 1759 . 
2 1 . G A R D N E R , I . D. , N . A. B O W E R N , and R. V . B L A N D E N . 1975 . Cell mediated 
cytotoxicity against ectromelia virus infected target cells. I I I . Role of the 
H - 2 gene complex. Europ. J . Immunol . 5: 122 . 
2 2 . B E V A N , M . J. 1975. Interaction antigens detected by cytotoxic T-cells with 
the major histocompatibility complex as modifier. Nature (Lond.) 256: 419. 
Dr. U . K O S Z I N O W S K I , Hygiene-Institut der Univers i t ä t Göt t ingen, Lehrstuhl 
Medizinische Mikrobiologie, Kreuzbergring 57 , D - 3 4 0 0 Göt t ingen. 
Author Index • 4 5 7 
Author Index 
A B B , J . 7 1 
A D E L M A N N , B . G. 3 6 9 
A L B E R T , E . D . 2 8 9 , 3 1 3 
A N D R E A S , A . 3 1 3 
A R E N D , P . 7 2 
A R N O L D , R . 3 4 0 
A R N O U X , A . 7 6 
A S M A , G. 107 
A U E R , I . O. 7 2 
A U G U S T I N , A . 73 
A V E R D U N K , R . 73 
A x , W . 7 4 
A X E L S S O N , J.-A. 167 
BACOURT, F . 7 6 
BARSOUM, A. L . 3 8 8 
BATSFORD, S. R . 3 8 1 
B A U C H I N G E R , M . 1 1 8 
B A U E R , H . W . 7 4 
B A U R , M . P . 2 0 9 
B E C K E R , U . 1 0 4 
B E N K E , W . 123 
B E N T L E Y , C . 4 0 2 
B E R G M A N N , B . 4 1 5 
BERTRAMS, J . 2 0 0 , 3 0 9 
BESSLER, W . 7 5 
B E Y E R , J . 3 0 9 
B I T T E R - S U E R M A N N , D . 
4 0 2 
B O C K H O R N , H . 7 6 
B O D E M E R , W . 3 8 1 
BOECKER, W . R . 105, 
4 2 3 
B Ö S I N G - S C H N E I D E R , R . 
7 6 
B O H N , H . 2 8 0 
B Ö T Z E N H A R D T , U . 77 , 9 8 
B R A O K E R T Z , D . 77 
B R A H E , V . 4 0 2 
B R A N D I S , H . 1 1 5 
B R A U N , D . G . 89 , 106 
B R A U N - F A L C O , O . 3 1 3 
BROECKER, E . - B . 78 
B R Ü G G E N , J . 78 
B R U N D E L R E , G . 2 6 6 
B U C H E L T , L . 87 
B U S C H M A N N , C H . 7 2 
B U S C H M A N N , H . 1 
B U T T L A R , B . V O N 120 
C I H A K , J . 7 9 
C I O L I , D . 7 9 , 9 4 
COHEN, S. 8 0 
CRAMER, M . 8 1 
C Z A R N E T Z K I , B . M . 96 
D A R A I , G . 9 2 
D E I C H E R , H . 1 1 1 
D I E M I N G E R , L . 82 , 2 3 1 
D I E R I C H , M . P . 8 2 
D I E T R I C H , M . 3 3 0 , 3 4 0 
D O H E R T Y , P . 87 
D Ö R R I E S , R . 83 
D O M I N G U E , G . J . 1 5 
D R E I K O R N , K . 3 1 6 
DROST, H . 3 0 9 
E I B L , M . 179 
E M M E R L I N G , P . 27 
E N D E R S , B . 1 2 4 
E N D L E R , A . T . 4 2 , 102, 
1 1 6 
E R T L , H . 128 
F A T H M A N , G . 8 4 
F A L K E N B E R G , F . 1 1 2 
F A R A H , F . S. 1 1 7 
F E R B E R , E . 8 4 
F I N G E R , H . 27 
F I N K , P . C. 1 1 1 
F ISCHER, H . 1 0 1 
F L A D , H . D . 190 , 326 , 
3 3 0 
F L I E D N E R , T . M . 3 2 6 
P R O H N WIESER, B . 1 
F U N K E , C. 9 0 
F U S E N I G , N . E . 3 2 3 
G A L A N o s , C. 8 4 
G A R R I D O , F . 1 1 4 
G A T T I , R . A. 9 8 
GATTRINGER, C. 123 
G A Y , S. 1 0 4 
GECZY, A . F . 8 5 
GECZY, C. L . 85 , 1 1 6 
G E I S E N , H . P . 85 , 2 7 3 
GEMSA, D . 8 6 , 1 1 9 
G E N T N E R , G . J . 3 6 9 
G I L L , I I I , T . J . 5 6 
G L E I C H M A N N , E . 8 6 
G L E I C H M A N N , H . 8 6 
GÖTZE, D . 87 
G O L D M A N N , S. F . 3 3 0 , 
3 3 5 , 3 4 0 
GRAMSE, M . 99 
G R E T I L L A T , P . A . 2 6 6 
GRIES , F . A . 3 0 9 
GROPP, C. 87 
G R O S S E - W I L D E , H . 7 1 , 
2 8 9 , 2 9 3 
G R U D E N , E . 106 
G R Ü N E K L E E , D . 3 0 9 
G R U N N E T , N . 3 3 5 
G Ü N T H E R , E . 103 
H A A S , R . J . 3 3 0 
H A D A M , M . 1.10 
H A D D I N G , U . 9 9 , 4 0 2 
H A M M E R , D . K . 103 
H Ä N S C H , G . 1 1 0 
H A N T K E , K . 7 5 
H A S K O V Ä , V . 3 6 3 
H A U P T , H . 2 8 0 
H A U S T E I N , D . 8 8 
H A V E M A N N , K . 87 , 99 
H E I D E , K . 2 8 0 
H E N R Y , R . 100 
H E N S S , J . 3 8 1 
H E S S , M . W . 2 6 6 
H U M A N S , W . 107 
H I L G E N F E L D T , U . 2 8 6 
H O C H , J . A . 8 2 
H Ö F E R , R . 1 0 1 
H O F F M A N N , G . W \ 8 8 
H O F F M A N N , L . G . 151 
H O F F M A N N - F E Z E R , G . 
109 
H R K A L , Z . 1 0 
H Ü B N E R , L . 1 1 3 
H U G E T , R . 190 , 3 2 6 
H U H N , D . 1 1 8 
H U N G E R E R , K . D . 74 , 
124 
H U S E R , H . 89 
H U S F E L D T , K . J . 7 4 
H Ü T T E R O T H , T . H . 89 
I N T O R P , H . W . 9 0 
J A N S E N , F . K . 3 0 9 
J O H A N N S E N , R . 90 , 2 8 0 
JOHNSON, E . J . 1 5 
J Ö K A Y , I . 3 4 3 
K Ä L L E N , B . 167 
K A L D E N , J . R . 105, 4 2 3 
K A R C Z A G , E . 3 4 3 
K A R E E M , H . A . 2 2 0 
K A U P P , E . 4 3 8 
4 5 8 • Author Index 
K E C K , K . 9 1 , 4 1 5 
K E L U S , A . 8. 122 
KERESZTESI , K . 42 
K E Y S S N E R , K . 9 2 
K I E F E R , H . 9 2 
K I R C H H O F F , W . 4 3 1 
K I R C H N E R , H . 92 
K I S S M E Y E R - N I E L S E N , F . 
335 
K L E I N , G . D . 1 5 
K L E Y , H . - P . 1 1 8 
K L I M E T Z E K , V . 93 
K L U G E , A . 103 
K N A P P , W . 93 , 107 
K N O P , J . 90 , 9 4 
K N O P P , P . M . 9 4 
K N Ü P F E R M A N N , H . 8 4 
K O B O W , U . 95 
K Ö N I G , W . 96 , 97 
K O J E R , M . 102 
K O L B , H . 9 6 
K O L B , H . J . 7 1 
KORCAKOVA, L . 3 6 3 
K O S Z I N O W S K I , U . 128 
K R A W I N K E L , U . 8 1 
K R E T H , H . W . 97 
KRESS, H . G . 7 2 
K R I S T E N S E N , T . 3 3 5 
K R Ü P E , H . 123 
K R U M B A C H E R , K . 326 
K U N T Z , B . 3 1 3 
K U N Z , H . W . 56 
K u o , C . -Y . 151 
K U W E R T , E . 2 0 0 , 309 , 3 8 8 
L A U E R , W . 103 
L A Z A R Y , S. 1 1 7 
L E H M A N N , K . 9 2 
L E H M A N N - G R U B E , F . 79 
L E I B O L D , W . 98 
L E M M E L , E . - M . 77 , 98 
L E N H A E D , V . 85 , 119, 
273 , 2 8 6 , 2 9 7 , 3 0 2 , 3 1 6 
L I C H T E N S T E I N , L . M . 96 
L I T W I N , S. D . 8 9 
LOCHER, G . W . 2 6 6 
L Ö F F L E R , C. 9 9 
L O H M A N N - M A T T H E S , M . L . 
101 
L O N G , D . 121 
LORACHER, A . 109 
LOSSE, H . 9 0 
L U D W I G , H . 1 0 1 , 112 , 
179 
L Y N E N , R . 82 , 231 
M A C H , B . 9 9 
M A C H E R , E . 78 
M Ä H L E R , B . 109 
M A N D E L , T . 8 8 
M A T S U K U R A , Y . 2 6 0 
M A T T E R , A . 100 
M A U R E R , H . R . 100 
M A Y K , W . R . 1 0 1 , 112, 
179, 2 0 9 
M E E R P O H L , H . G . 1 0 1 
MEINGASSNER, J . G . 93 
M E N Z E L , J . 4 2 , 102 , 116 , 
141 
M E R Z , W . E . 2 8 6 
M I L L E R , J . A . F . P . 77 
M I T C H E L L , G . F . 77 
M O N C K T O N , P . 102 
M O N D O R F , A . W . 1 1 2 
M O R O N I , C H . 102 
MOSSMANN, H . 103 
M Ü L L E R , M . 2 7 
M Ü L L E R - R U C H H O L T Z , YY. 
3 0 6 
M Ü N K , K . 9 2 
X A E I M , F . 9 8 
X E T Z E L , B . 289 , 2 9 3 
N I E T H A M M E R , D . 3 3 0 
N Ü S S E N , J . 72 
N O R D I N , A . 73 
N ORTHO FF, G . F L 103 
X R OTHDÜRFT, W . 3 2 6 
N O W A C K , H . 104 
O E H L , S. 105 , 4 2 3 
OCTLVIE, B . M . 105 
OPITZ, H . G . 190 
OTZ, U . 1 0 6 
PABST, R . 4 3 8 
P A L U S K A , E . 1 0 
P A W L I T A , M . 106 
P E L L E G R I N O , M . A . 82 
P E T E R , H . H . 105, 4 2 3 
P F I Z E N M A I E R , K . 107, 
1 1 7 
P F L I E G E R , H . 3 4 0 
P I C H L E R , W . J . 107 
P I C H L M A Y R , R . 124 
P O L A K , L . 108 
R A B B I T T S , T . H . 108 
R A H M A N , A . 1 1 5 
R A J E W S K Y , K . 8 1 
R E I S , H . E . 3 0 9 
R E N E L T O V Ä , I . 363 
RESCH, K . 75 , 103, 109 
R I C H T E R , E . 123, 3 5 1 
R I E B E R , E . P 1 1 0 
R I E D E R , I . 7 1 
R I E S E N , W . F . 89 
R I E T H M Ü L L E R , G . 1 1 0 
R I T T N E R , C H . 2 0 9 , 2 8 9 
R I T Z , E . 3 1 6 
R O D T , H . V . 7 1 , 109, 1 1 8 
R Ö H L , L . 3 1 6 
R o E L C K E , D . 85 , 273 
R Ö L L I N G H O F F , M . 107, 
1 1 7 
R Ö H N ACHER, R . 1 1 5 
R O T H , V . 97 
R O T H E R , K . 1 1 0 
R O T H E R , U . 1 1 0 
R U N N E N B A U M , B . 2 9 7 
R U P P E K T , W . 2 9 3 
RÜSSEL, R . A . 82 
S A A L , J . G . 1 1 0 
SCHACKERT, K . 286 , 297 
SCHAEFER, U . W . 105, 
4 2 3 
SCHAUENSTEIN, K . 1 1 1 
SCHEDEL, I . I I I 
SCHERBERICH, J . E . 1 1 2 
SCHERNTHANER, G . 1 0 1 , 
112, 179 
SCHIESSL, B . 3 1 3 
SCHIMPL, A . 83 , 1 1 3 
SCHIRRMACHER, V . 1 1 4 
SCHMASSMANN, E . 77 
SCHMIDT, G . 120 
SCHMIDT, W . 99 , 2 7 3 , 
2 8 6 , 2 9 7 
SCHNAPPAUF, H . P . 3 2 6 
»SCHNEIDER, C. H . 1 0 6 
SCHOEFFINTUS, H . 3 1 3 
SCHÖNER, W . 1 1 1 
SCHOLZ, S. 2 8 9 , 3 1 3 
SCHULER, W . 1 1 4 
S C H U M A N N , G . 102 
SCHWICK, H . G . 124, 2 8 0 
SEDLACEK, FL. H . 9 0 , 9 4 
SEELIG, H . P . 1 1 5 
SEELIG, R . 1 1 5 
SEIBERT, E . 78 
SEILER, F . R . 90 , 9 4 , 2 8 0 
S E T H I , K . K . 1 1 5 
SMOLEN, J . 4 2 , 102, 1 1 6 
SORG, C. 78 , 93 , 116 , 4 3 1 
SPIESS, H . 3 4 0 
SPRENGER, R . 122 
Author Index • 4 5 9 
STADLER, B . 1 1 7 
ST A R Z I N SK Y - P O W I T Z , A. 
107, 117 , 1 2 1 
STEFFEN, C. 4 2 , 102 
STEGGEMANN, L . 8 6 
S T E I N , G . 3 3 0 
S T E I N B A C H , I . 3 2 6 
S T E I N H A U S E N , G . 3 0 6 
STINGL, G . 9 3 
STOCKING ER, B . 9 8 
STOECK, M . 109 
STÖFFLER, G . 120 
SUCIU-FOCA, X . 2 8 9 
S YOB OD A, J . 3 6 3 
SZIEGOLEIT, A . 2 4 4 
T E I C H , N . 102 
T H I E L , E . 1 1 8 
T H I E R F E L D E R , S. 7 1 , 
109, 1 1 8 
THOMPSON, J . J . 1 5 1 
T I L L , G . 1 1 9 
T I M P L , R . 104 
T I S C H E N D O R F , F . W . 
119 , 120 
T I T T O R , W . 2 9 9 , 3 0 2 
T R E P E L . F . 4 3 8 
T ü R K O V Ä , B . 1 0 
U H L E N B R U C K , G . 2 2 0 
V A D A S , M . 77 
V A I M A N , M . 7 6 
V O G T , W . 8 2 , 1 2 0 , 2 3 1 , 3 8 1 
W A D E , I . 123 
W A G N E R , H . 107 , 117, 1 2 1 
W A L F O R D , R . L . 98 
W E C K , A . L . D E 85 , 106, 
1 1 7 
W E C K E R , E . 8 3 , 1 2 1 
W E I D I N G E R , P . 1 1 6 
W E I L E R , E . 95 , 122 
W E I L E R , I . J . 122 
W E I S S , S. 122 
W E L L E N S I E K , H . - J . 123 
W E S T P H A L , E . 3 0 6 
W E T Z M Ü L L E R , H . 3 1 3 
W I C K , G . l l l , 123, 3 5 1 
W I E G A N D , G . 97 
W O N I G E I T , K . 124 , 3 2 0 
WORST, P . K . M . 3 2 3 
Y O U N G C H A I Y U D , U . 102 , 
1 1 6 
Z l E G L E R , E . 3 1 3 
Z I M M E R M A N N , A . 2 6 6 
Z W I S L E R . O . 124 
460 • Subject Index 
Subject Index 
Addisons's disease, immuni ty to 
adrenal antigens in 179 
Adjuvant act ivi ty of protamine 
hydrochloride 190 
Adrenal antigens, immuni ty to . 179 
Alpha-1 -foetoprotein 72 
Alternative C pathway, inter-
action wi th zymosan 402 
Antibodies after S. typhimur ium 
infection 244 
Antibody, quanti ty synthesized 
in a single cell 381 
Arthus reaction, induction of . . 42 
Cold agglutinins to I / i and Pr 
antigens 273 
Collagen anti-collagen immune 
complexes 141 
Collagen, antibody response to 
and the antigenic conformation 369 
Collagen, antibody response to in 
guinea pigs 369 
Collagen, collagenase digestion of 141 
Complement, first component . . 151 
Cytotoxicity, cell-mediated . . . 128 
Cytotoxic lymphocytes, lysis of 
different target cells 128 
Enterobacterial antigen, the ana-
tomical locus of the 15 
Escherichia coli, common entero-
bacterial antigen of 15 
Factor D , purification and prop-
erties 231 
Fluoro-immuno-cytoadherence, a 
method for identification of 
antigen-binding cells 351 
Galactans in Achatina fulica . . 220 
a - Galactosyl transferase act ivi ty 
in frogs 260 
Globin, antigenic relationship be-
tween human and canine . . . 10 
Glucose metabolism during pha-
gocytosis 1 
Glycosubstances in Achatina 
fulica 220 
Hemagglutination inhibit ion . . 15 
Hemoglobin, human and canine . 10 
Heparin, effect of on the priming 
wi th antigen 343 
Histocompatibil i ty, new loci in 
man 335 
H L A , analyses of B W 2 1 and 
B W 4 0 . 306 
H L A and atopic dermatitis . . . 313 
H L A and plausibility of paternity 209 
H L A antigens and immunere-
sponsivenes to insulin . . . . 309 
H L A - B / D recombination fre-
quency 289 
H L A - D alleles in the german po-
pulation 277 
H L A in multiple sclerosis. . . . 200 
I g E levels in a normal human 
population 388 
I m m u n i t y to adrenal antigens. . 179 
Immunization, maternal, on the 
survival and postnatal deve-
lopment of the offspring . . . 42 
Immunization, postnatal wi th 
DNP-BGG 42 
Immunization, pulpal 42 
Immunization w i t h bovine en-
cephalitogenic protein, effect of 
on thoracic duct cell M L R . . 167 
Immunodeficiency, combined, re-
constitution wi th bone marrow 337 
Immunoglobulins after S. typhi-
mur ium infection 244 
Immunosuppression, antibody-
mediated 27 
I r gene control of carrier recogni-
t ion 415 
Kidney transplantation wi thin 
families 316 
Lymphocyte nucleoli changes and 
allografts 363 
Lymphocyte transformation, in-
hibi t ion by oestrogen and ges-
tagene 297 
Lymphocytes, inhibi t ion of the 
transformation by chorionic 
gonadotropin 286 
Lymphokines, no direct activa-
t ion of fluid phase C 3 . . . . 431 
Mixed leukocyte reaction in rats 167 
MLC, age dependence of thymus 
and lymph node cells . . . . 299 
Subject Index • 461 
MLC data and a computer pro-
gram 293 
MLC, inhibi t ion of by proteins . 280 
MLC, suppression of specific re-
sponsiveness 320 
MLC, synergy of thymus and 
lymph node cells 302 
Mult iple sclerosis, H L A antigens 
in 200 
Null-lymphocytes, a highly en-
riched pool for granulocytic 
stem cells 423 
Ovalbumin agar gel, deposition 
into the pulpal room 42 
Paternity, plausability in the 
H L A system 209 
Phagocytosis of bacteria . . . . 1 
Phagocytosis, stimulated glucose 
oxidation 1 
Plasma cell population, mono-
clonal in the uterus 266 
Properdin system, factor D . . . 231 
Protamine hydrochloride, adju-
vant and suppressor act iv i ty . 190 
Rosette formation of pig lympho-
cytes 438 
Salmonella typhimur ium . . . . 15 
S. typhimur ium infection, im-
munoglobulins and antibodies 244 
Suppressor act iv i ty of protamine 
hydrochloride 190 
Transfusion, granulocytes and 
H L A antigens 340 
Transplantation, bone marrow i n 
patients 330 
Transplantation of allogeneic ca-
nine marrow 71 
Transplantation of allogeneic dog 
leukocytes 326 
Transplantation, re- of cultured 
murine epidermal cells . . . . 323 
Zymosan, interaction wi th the 
alternative C pathway . . . . 403 
